The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $63.75

Today's change-0.43 -0.67%
Updated October 18 2:13 PM EDT. Delayed by at least 15 minutes.
 

Bristol-Myers Squibb Co

NYSE: BMY
Last

(U.S.) $63.75

Today's change-0.43 -0.67%
Updated October 18 2:13 PM EDT. Delayed by at least 15 minutes.

Bristol-Myers Squibb Co crosses below 20-day moving average

Bristol-Myers Squibb Co is lower today, dropping (U.S.)$0.43 or 0.67% to (U.S.)$63.75 and crossing below its 20-day moving average. Shares have lost 2.09% over the last five days, but sit 3.56% below their 52-week high. This security has outperformed the S&P 500 by 7.55% during the last year.

Key company metrics

  • Open(U.S.) $64.25
  • Previous close(U.S.) $64.18
  • High(U.S.) $64.70
  • Low(U.S.) $63.55
  • Bid / Ask(U.S.) $63.75 / (U.S.) $63.76
  • YTD % change+9.09%
  • Volume3,283,669
  • Average volume (10-day)5,226,157
  • Average volume (1-month)5,841,223
  • Average volume (3-month)6,319,875
  • 52-week range(U.S.) $46.01 to (U.S.) $66.10
  • Beta1.18
  • Trailing P/E23.23×
  • P/E 1 year forward21.51×
  • Forward PEG2.09×
  • Indicated annual dividend(U.S.) $1.56
  • Dividend yield2.45%
  • Trailing EPS(U.S.) $2.74
Updated October 18 2:13 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+22.54%

Based on its net profit margin of 22.54%, Bristol-Myers Squibb Co is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.06%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue5,1444,9295,2434,922
Total other revenue--------
Total revenue5,1444,9295,2434,922
Gross profit3,7123,6703,8663,624
Total cost of revenue1,4321,2591,3771,298
Total operating expense3,8092,9684,1153,369
Selling / general / administrative1,1671,0741,4611,144
Research & development1,1701,0911,3871,138
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)725-25730-53
Other operating expenses, total-685-199-140-158
Operating income1,3351,9611,1281,553
Interest income (expense), net non-operating-52-45-40-42
Gain (loss) on sale of assets--------
Other--------
Income before tax1,2951,9551,0861,559
Income after tax9221,5268981,215
Income tax, total373429188344
Net income9161,5748941,202
Total adjustments to net income--------
Net income before extra. items9161,5748941,202
Minority interest-648-4-13
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9161,5748941,202
Inc. avail. to common incl. extra. items9161,5748941,202
Diluted net income9161,5748941,202
Dilution adjustment--------
Diluted weighted average shares1,6501,6711,6831,679
Diluted EPS excluding extraordinary itemsvalue per share0.560.940.530.72
Dividends per sharevalue per share0.390.390.380.38
Diluted normalized EPSvalue per share0.870.820.550.69